Inhibikase Therapeutics Inc (IKT)

$1.72 +0.05 (2.99%)
Market Cap 129.30M
Revenue (ttm) 0.00
Net Income (ttm) -27.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 742,100
Avg Vol 302,910
Day's Range N/A - N/A
Shares Out 75.18M
Stochastic %K 90%
Beta 0.88
Analysts Strong Sell
Price Target $6.25

Company Profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia....

Industry: Biotechnology
Sector: Healthcare
Phone: 678 392 3419
Address:
3350 Riverwood Parkway SE, Suite 1900, Atlanta, United States
DARKP00L
DARKP00L Dec. 11 at 3:01 PM
$IKT 09:57 on Dec. 11 2025 Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 2:57 PM
Cantor Fitzgerald has adjusted their stance on Inhibikase Therapeutics ( $IKT ), setting the rating to Overweight with a target price of 4.
0 · Reply
Drugtrade
Drugtrade Dec. 5 at 3:19 PM
$IKT hi risk hi reward one trick pony.. i dont pretend to be a biochemist or like id understand 99% of any study on PDGFRα/PDGFRβ/c-KIT (whatever tf that is) but i can say if this isnt a scam we will see 300 to 500m market cap valuation with positive phase 2 readout
1 · Reply
BioMan_67
BioMan_67 Dec. 3 at 4:21 AM
$IKT just bought back in after selling earlier this year. Made some money on that trade and hoping for more of the same!
0 · Reply
BillyTheKid62
BillyTheKid62 Nov. 26 at 8:15 PM
$IKT Owning this stock is bad for my health !
0 · Reply
WallStpolitician
WallStpolitician Nov. 26 at 12:09 AM
$IKT if I buy enough of this stock I will take it to like $8 myself
0 · Reply
TJC1791
TJC1791 Nov. 24 at 11:59 PM
$IKT If I’m reading this correctly Sands Capital, major shareholder added as part of this new raise. 🤔 and yeah they still have a mountain of warrants at their disposal. https://ir.stockpr.com/inhibikase/sec-filings-email/content/0001875620-25-000025/primary_doc.html
0 · Reply
TJC1791
TJC1791 Nov. 21 at 9:46 PM
$IKT more shares, more games. 3m vol (avg 100k). Up 19% premarket, close red. Here we go.
1 · Reply
RunnerSignals
RunnerSignals Nov. 21 at 8:08 PM
$IKT Institutions loading before $100M offering follow the smart money carefully
1 · Reply
BillyTheKid62
BillyTheKid62 Nov. 21 at 3:15 PM
$IKT Only thing that's gonna happen is a reverse split in a year .
0 · Reply
Latest News on IKT
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 20, 2025, 9:54 PM EST - 4 weeks ago

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 20, 2025, 4:12 PM EST - 4 weeks ago

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Nov 20, 2025, 4:01 PM EST - 4 weeks ago

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Nov 14, 2025, 4:01 PM EST - 5 weeks ago

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Aug 19, 2025, 8:00 AM EDT - 4 months ago

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

Aug 14, 2025, 4:50 PM EDT - 4 months ago

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

May 14, 2025, 4:05 PM EDT - 7 months ago

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Apr 14, 2025, 8:00 AM EDT - 8 months ago

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Mar 27, 2025, 4:01 PM EDT - 9 months ago

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Inhibikase Announces Expansion of Senior Leadership Team

Feb 24, 2025, 8:00 AM EST - 10 months ago

Inhibikase Announces Expansion of Senior Leadership Team

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Feb 18, 2025, 8:00 AM EST - 10 months ago

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Jan 29, 2025, 6:30 PM EST - 11 months ago

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

Nov 19, 2024, 1:32 PM EST - 1 year ago

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Nov 14, 2024, 8:37 AM EST - 1 year ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Oct 21, 2024, 9:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Oct 9, 2024, 9:18 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 6:13 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Aug 14, 2024, 4:25 PM EDT - 1 year ago

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Jun 17, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Jun 5, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

May 20, 2024, 8:01 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript

May 17, 2024, 9:57 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

May 15, 2024, 8:00 PM EDT - 1 year ago

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

May 15, 2024, 8:45 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

May 9, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Apr 18, 2024, 4:30 PM EDT - 1 year ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Apr 3, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 5:13 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Mar 27, 2024, 4:15 PM EDT - 1 year ago

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Mar 7, 2024, 8:30 AM EST - 1 year ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Feb 28, 2024, 4:05 PM EST - 1 year ago

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Feb 7, 2024, 7:55 AM EST - 2 years ago

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Jan 29, 2024, 9:05 AM EST - 2 years ago

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Jan 16, 2024, 4:05 PM EST - 2 years ago

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Dec 4, 2023, 8:35 AM EST - 2 years ago

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript

Nov 15, 2023, 5:38 PM EST - 2 years ago

Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Nov 14, 2023, 4:30 PM EST - 2 years ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

Nov 7, 2023, 9:28 AM EST - 2 years ago

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

Oct 4, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Aug 24, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Aug 21, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Aug 17, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Aug 7, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jul 17, 2023, 4:05 PM EDT - 2 years ago

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

Jun 29, 2023, 9:29 AM EDT - 2 years ago

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Jun 22, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

DARKP00L
DARKP00L Dec. 11 at 3:01 PM
$IKT 09:57 on Dec. 11 2025 Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 2:57 PM
Cantor Fitzgerald has adjusted their stance on Inhibikase Therapeutics ( $IKT ), setting the rating to Overweight with a target price of 4.
0 · Reply
Drugtrade
Drugtrade Dec. 5 at 3:19 PM
$IKT hi risk hi reward one trick pony.. i dont pretend to be a biochemist or like id understand 99% of any study on PDGFRα/PDGFRβ/c-KIT (whatever tf that is) but i can say if this isnt a scam we will see 300 to 500m market cap valuation with positive phase 2 readout
1 · Reply
BioMan_67
BioMan_67 Dec. 3 at 4:21 AM
$IKT just bought back in after selling earlier this year. Made some money on that trade and hoping for more of the same!
0 · Reply
BillyTheKid62
BillyTheKid62 Nov. 26 at 8:15 PM
$IKT Owning this stock is bad for my health !
0 · Reply
WallStpolitician
WallStpolitician Nov. 26 at 12:09 AM
$IKT if I buy enough of this stock I will take it to like $8 myself
0 · Reply
TJC1791
TJC1791 Nov. 24 at 11:59 PM
$IKT If I’m reading this correctly Sands Capital, major shareholder added as part of this new raise. 🤔 and yeah they still have a mountain of warrants at their disposal. https://ir.stockpr.com/inhibikase/sec-filings-email/content/0001875620-25-000025/primary_doc.html
0 · Reply
TJC1791
TJC1791 Nov. 21 at 9:46 PM
$IKT more shares, more games. 3m vol (avg 100k). Up 19% premarket, close red. Here we go.
1 · Reply
RunnerSignals
RunnerSignals Nov. 21 at 8:08 PM
$IKT Institutions loading before $100M offering follow the smart money carefully
1 · Reply
BillyTheKid62
BillyTheKid62 Nov. 21 at 3:15 PM
$IKT Only thing that's gonna happen is a reverse split in a year .
0 · Reply
DaBullRunner
DaBullRunner Nov. 21 at 2:14 PM
HERZ no one believes me…… Until it happens……. Getting in BEFORE it happens…..👇🚨👇🚨👇🚨👇 $MFI $SGMO $SMX $IKT $KTTA what a morning
0 · Reply
cw9c
cw9c Nov. 21 at 2:00 PM
$IKT why’s this rising? That’s a massive offering
0 · Reply
topstockalerts
topstockalerts Nov. 21 at 1:58 PM
Pre Market Top Gainers PT2 $CTOR $LXEH $ILAG $IKT $TELO
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 21 at 1:01 PM
$IKT partial batman robin
0 · Reply
makny
makny Nov. 21 at 12:09 PM
$IKT may see a new 52 week low, thanks to the offering
0 · Reply
topstockalerts
topstockalerts Nov. 21 at 12:05 PM
Pre Market Top Gainers PT2 $EPSM $SHPH $IKT $CBC.X $ILAG
0 · Reply
Stmkr
Stmkr Nov. 21 at 6:50 AM
$IKT I like the potential but huge number of warrants. Including new offering fully diluted share count is around 350M. Interim readout guided for mid 2028 Topline mid 2029 Looong wait. Will probably drift sideways / or down fir a while
1 · Reply
AlertsAndNews
AlertsAndNews Nov. 21 at 3:40 AM
$IKT headline and offering right after. Smh Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants "today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of common stock. The shares of common stock are being sold at an offering price of $1.45 per share"
0 · Reply
TJC1791
TJC1791 Nov. 21 at 3:26 AM
$IKT https://www.inhibikase.com/news/press-releases/detail/137/inhibikase-therapeutics-announces-pricing-of-100-million
0 · Reply
TJC1791
TJC1791 Nov. 21 at 12:43 AM
$IKT ouch
0 · Reply
TJC1791
TJC1791 Nov. 20 at 10:17 PM
$IKT https://ir.stockpr.com/inhibikase/sec-filings-email/content/0001193125-25-289894/d944552d424b5.htm
0 · Reply
Cmash1
Cmash1 Nov. 20 at 10:13 PM
$AUID $IKT $KTTA $NVVE $ZONE adding more ZONE
1 · Reply